Feed/Companies/Anagram Therapeutics

Anagram Therapeutics

As of 14 Oct 2026, Anagram Therapeutics has raised $250M across 1 verified round on record; latest: $250 million funding round, announced 7 May 2026.

BUILT ON

Visit site

Anagram Therapeutics develops breakthrough orally delivered enzyme therapeutics for rare and life-threatening diseases, primarily targeting malabsorption syndromes and nutrient metabolism disorders.

anagramtx.comNatick, MA

LATEST ROUND

Funding round

$250M · 2026-05-07

RAISED ON RECORD · USD

$250M

across 1 verified round

INVESTORS

no lead named

SOURCES

from 1 publisher

Rounds

[ 1 ]

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Funding round

$250M · 2026-05-07

[ HISTORY ]

lead not stated

Round	Amount	Announced	Lead	Buzz
Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$250M	2026-05-07	not stated	No recent discussion
1 source [ VERIFIED · CORRECTED ] read against 1 source The source does not state a financing stage or valuation. The Cystic Fibrosis Foundation is identified as having provided earlier funding, not as an investor in this investment. Published by hand (blackstone.com): "Blackstone Life Sciences (“BXLS”) today announced a $250 million investment in Anagram Therapeutics (“Anagram”)...": biggest-rounds completeness (K): hand-checked, the cited page states $250 million

Anagram Therapeutics

Rounds

Company

Rounds

Sources

Profile

Investors

Anagram Therapeutics

Rounds

Profile

Sources

Funding round$250M2026-05-071 source

Investors

Funding round$250M2026-05-071 investor